Executive Director of Clinical Pharmacology, Translational Medicine
Alpine Immune Sciences
Dr. Rupert Davies currently serves as Executive Director of Clinical Pharmacology within Translational Medicine at Alpine Immune Sciences, where he is responsible for the PK/PD modeling to enable dose/regimen selection and PopPK modeling/ER analysis of drug candidates. Previously at Zymeworks, Dr. Davies enabled the advancement of zanidatamab to two ongoing registrational clinical trials and zanidatamab zovodotin into the clinic by combining bispecific and ADC platforms to develop drug candidates with expanded therapeutic windows. Throughout his career, he has worked in various roles of increasing responsibility at small start-ups, medium-sized biotechs and Amgen on a broad array of drugs modalities from small molecules/peptides to RNA mimics and multi-functional protein fusion/bispecific antibodies, including six candidates that are currently being evaluated in clinical trials and two approved drugs. He received his PhD in Bioengineering from the University of Utah and completed a post-doctoral fellowship in Bioengineering at the University of Washington.